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Abstract 
Hypertension, the most common preventable risk factor for cardiovascular disease and death, 
is a growing health burden. Serious cardiovascular complications result from target organ 
damage including cerebrovascular disease, heart failure, ischaemic heart disease and renal 
failure.  While many systems contribute to blood pressure elevation, the vascular system is 
particularly important, because vascular dysfunction is a cause and consequence of 
hypertension. Hypertension is characterised by a vascular phenotype of endothelial 
dysfunction, arterial remodelling, vascular inflammation and increased stiffness. Anti-
hypertensive drugs that influence vascular changes associated with high blood pressure have 
greater efficacy for reducing cardiovascular risk than drugs that reduce blood pressure but 
have little or no effect on the adverse vascular phenotype.  Angiotensin converting enzyme 
(ACE) inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) improve endothelial 
function and prevent vascular remodelling. Calcium channel blockers also improve 
endothelial function, although to a lesser extent than ACEI and ARBs.  Mineralocorticoid 
receptor antagonists improve endothelial function and reduce arterial stiffness and have 
recently become more established as anti-hypertensive drugs.  Lifestyle factors are essential 
in preventing the adverse vascular changes associated with high blood pressure and reducing 
associated cardiovascular risk.   Clinicians and scientists should incorporate these factors into 
treatment decisions for patients with high blood pressure, as well as in the development of 
new anti-hypertensive drugs that promote vascular health.   
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Key Points 
• Hypertension is characterized by a vascular phenotype of endothelial 
dysfunction and structural remodeling. 
• Anti-hypertensive drugs that target the vascular changes associated with 
hypertension appear to be most efficacious  
• New anti-hypertensive drugs should promote vascular health as well as reducing 
blood pressure   
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1. Introduction 
Hypertension is a common chronic condition that affects 30% of the adult population1.  It is 
the largest contributor to the global burden of cardiovascular disease and represents the most 
important modifiable risk factor for stroke, ischaemic heart disease, heart failure, renal failure 
and peripheral vascular disease2,3.  The World Health Organisation (WHO) estimates that the 
global prevalence of hypertension will increase by 50% from 1 billion to 1.5 billion adults by 
20202.  Effective blood pressure control is therefore an urgent and essential public health 
priority to prevent the significant cardiovascular morbidity and mortality that can result from 
the potentially serious clinical complications and sequelae associated with hypertension3.   
Hypertension is associated with structural, mechanical and functional changes within the 
vasculature that contribute to a vascular phenotype characterised by increased arterial 
stiffness, reduced elasticity, increased vascular tone and endothelial dysfunction2. Molecular 
mechanisms contributing to these vascular changes involve reduced nitric oxide (NO) 
bioavailability,  increased production of reaction oxygen species (ROS) (oxidative stress), 
increased intracellular free Ca2+ concentration,  activation of pro-inflammatory and mitogenic 
signalling pathways and vascular fibrosis and calcification4.  Although many different classes 
of anti-hypertensive drugs are currently available, more than 70% of patients with 
hypertension continue to have elevated blood pressure and sub-optimal control. The 
importance of hypertension as a risk factor for cardiovascular diseases and all-cause mortality 
was recently highlighted in the SPRINT study, which demonstrated that aggressively 
lowering systolic blood pressure to less than 120 mmHg is associated with a significant 
reduction in major cardiovascular events and death5. Accordingly treating to optimal blood 
pressure targets is essential in reducing hypertension complications and cardiovascular risk.  
Hypertension-associated cardiovascular complications are prevented or ameliorated by 
antihypertensive drugs through blood pressure lowering and through direct effects on target 
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organs. It is becoming increasingly apparent that some antihypertensive drugs, such as 
angiotensin-converting enzyme (ACE) inhibitors (ACEI), angiotensin II receptor blockers 
(ARB) and mineralocorticoid receptor blockers amongst others, may have a direct effect on 
cardiac, renal and vascular function. Accordingly, drugs that lower blood pressure and that 
are organ-protective are likely to have added benefit. In particular, there is growing interest in 
targeting the vascular system to prevent or repair vascular damage and to promote vascular 
health6. Here we provide a discussion from review of contemporary literature that highlights 
the vascular changes which characterise hypertension and discuss the importance of targeting 
the vasculature from a therapeutic viewpoint. 
2. Vascular biology of hypertension 
The vascular biology of hypertension involves a phenotype that is characterised by 
functional, structural and mechanical changes that include endothelial dysfunction, vascular 
remodelling, inflammation, calcification and increased arterial stiffness (Figure 1)2,6.  These 
changes reduce the ability of arteries to react and adapt to tissue oxygen demands and 
culminate in tissue ischaemia, infarction and injury2.  The overall vascular phenotype 
depends on multiple interacting factors including genetics, physiological systems, diet, 
smoking, diabetes, dyslipidaemia and obesity2,7,8.  When these factors are combined with pro-
hypertensive factors there is exaggerated vascular injury and arterial stiffening. Experimental 
and clinical studies demonstrate that the vascular phenotype of young hypertensive patients 
resembles that of healthy elderly patients, which has led to the concept that hypertension 
results in early vascular ageing2. 
Arterial stiffening results from excessive fibrosis, with associated collagen deposition, elastin 
fibre fragmentation and degeneration, laminar medical necrosis, calcification and collagen 
cross-linking by advanced glycation end-products2.  Fibrosis initially occurs as a reversible 
and adaptive repair process that subsequently progresses and extends into the neighbouring 
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interstitial spaces with further arterial stiffening2.  In large vessels, arterial stiffening reduces 
the pressure damping effects of normal vascular elasticity that serves to protect the peripheral 
vasculature under normal conditions. In peripheral arteries, the vessels important in blood 
pressure regulation, increased fibrosis and arterial stiffness contribute to impaired endothelial 
function, increased vasomotor tone, vascular rarefaction and reduced tissue perfusion2,9.   
The pro-hypertensive phenotype involves activation of the renin-angiotensin-aldosterone 
system (RAAS), vascular inflammation, oxidative stress, excessive salt consumption and 
genetic factors, which contribute to extracellular matrix deposition and amplification of 
hypertension-associated vascular injury. The excessive fibrosis extends from small arteries to 
replace parenchymal tissue, resulting in tissue fibrosis, scarring and target organ damage.  In 
hypertension, these changes typically affect the heart, brain and kidney and can therefore lead 
to the clinical consequences and complications often seen in patients with inadequately 
controlled hypertension, including heart failure, cerebrovascular disease, ischaemic heart 
disease and renal failure2. 
Molecular and cellular mechanisms that underpin the vascular changes associated with 
hypertension include reduced NO production, increased ROS generation, aberrant signal 
transduction, pro-inflammatory and pro-fibrotic transcription factor activation, reduced 
collagen turnover, vascular calcification, smooth muscle cell proliferation and extracellular 
matrix (ECM) remodelling2,6.  The overall result is further increased fibrosis and damage, 
which can lead to a feed-forward amplifying phenomenon.  This is exacerbated by increased 
levels of of pro-hypertensive vasoactive factors, including angiotensin II (Ang II), 
endothelin-1 (ET-1) and aldosterone. These agents stimulate pro-fibrotic and mitogenic 
signalling cascades that include p38mitogen-activated protein kinases (p38MAPK), 
extracellular signal regulated kinases 1/2 (ERK1/2) and transforming growth factor-β (TGF-
β)/SMAD,  activation of pro-inflammatory transcription factors, increased galectin-3 and 
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dysregulation of matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs). Signalling through these pathways contribute to extra-cellular 
matrix remodelling and result in further vascular fibrosis2. 
3. Endothelial dysfunction 
The vascular endothelium is a monolayer of cells that forms the lining of all blood vessels 
and plays an essential role in vascular function through the synthesis and release of 
biologically active substances that act in an autocrine or paracrine fashion to influence 
vascular tone and function4,6.  Examples include NO, prostacyclin (PGI2) and endothelium 
derived hyperpolarising factor (EDHF)4.  NO is the best characterised relaxing factor and is 
derived from transformation of L-arginine into citrulline via NO synthase (NOS) which is 
constitutively expressed in endothelial cells10-13.  NO may also be produced and released 
under the influence of stimuli such as acetylcholine, bradykinin, substance P, serotonin, and 
mechanical shear stresses4.  The endothelium also produces endogenous vasoconstrictors, 
such as endothelin-1 (ET-1), which is particularly potent4,14,15.  Human ET-1 is derived from 
pre-pro-ET-1 which is enzymatically cleaved to form big ET-1 which is further processed to 
form the active peptide by endothelin-converting enzyme16.  ET-1 acts through ETA and ETB 
receptors.  ETA receptors are found on vascular smooth muscle cells where they promote 
vasoconstriction, whilst ETB receptors are found on both endothelial and smooth muscle 
cells17,18.  Activation of smooth muscle ETB receptors promotes vasoconstriction, whereas 
endothelial cell ETB receptors induce vasodilatation through production of substances such as 
NO and PGI218-20.  The magnitude of the the vasoconstrictor effect of ET-1 therefore depends 
upon the relative balance between vasoconstriction mediated via vascular smooth muscle cell 
ETA and ETB receptors, and vasodilatation due to upregulation of NO and PGI2 activity via 
endothelial cell ETB receptors4,21. 
 7 
Healthy endothelium has a vasodilator, anti-inflammatory and anti-thrombotic phenotype, 
whilst endothelial dysfunction is characterised by an endothelium that is pro-inflammatory, 
pro-thrombotic with impaired vasodilator responses6.  Endothelial dysfunction is a central 
component of the phenotypical changes that occur in the development of hypertension and is 
associated with increased atherosclerosis and cardiovascular risk1.  
3.1 Measuring Endothelial Function 
Endothelial function can be measured functionally using invasive and non-invasive 
techniques that assess vasodilator responses to pharmacological or mechanical stimuli, such 
as bradykinin, acetylcholine or shear stresses1.   Vasodilator responses are mainly related to 
NO production, which is released by healthy and intact endothelium via eNOS1,6. Reduced 
NO bioavailability is a key characteristic of endothelial dysfunction, and results in part from 
increased ROS generation which inhibits eNOS activity6.    Endothelial dysfunction can also 
be detected at the cellular and molecular level by assessing endothelial cell proliferation, 
platelet adhesion/aggregation, vascular permeability and leucocyte/endothelial cell 
interactions22.   
Invasive methods of assessing endothelial function, such as those performed in the coronary 
arteries using acetylcholine or pharmacologically-induced flow manipulation, have largely 
been superseded by simpler, cheaper and less invasive methods.  These include brachial 
artery flow-mediated dilatation and venous occlusion plethysmography1,23. Severity of 
hypertension correlates with impairment of endothelial function and anti-hypertensive 
therapies that improve endothelial function in addition to lowering blood pressure may be 
associated with greater improvements in overall cardiovascular risk1,24,25. 
In vitro methods of assessing endothelial function include evaluation of endothelium-
dependent relaxation or dilatation in isolated arteries from hypertensive patients using 
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agonists such as acetylcholine, bradykinin, substance P, ADP, serotonin and histamine.  
Circulating markers of endothelial function include NO metabolites, pro-inflammatory 
markers such as intracellular adhesion molecules, selectins, and markers of fibrinolysis, such 
as tissue plasminogen activator and plasminogen activator inhibitor. Endothelial 
microparticles have also recently emerged as a novel marker of endothelial function22. 
3.2 Endothelial Dysfunction and Hypertension 
Endothelial dysfunction is recognised as a hallmark of the vascular phenotype in patients 
with hypertension and many studies have demonstrated impaired endothelial function in 
patients with hypertension4,26-34.  Patients with hypertension have reduced forearm blood flow 
responses to acetylcholine and bradykinin at the level of resistance arteries, whilst alterations 
in flow-mediated vasodilatation have been observed in large epicardial coronary arteries of 
hypertensive patients22,26,34-37.   
3.3 Mechanisms of Hypertension-Associated Endothelial Dysfunction 
Reduced NO bioavailability is central to the pathophysiology of endothelial dysfunction 
associated with hypertension, which mainly results from reduced NO production and 
increased inactivation due to oxidative stress and vascular inflammation1,22,38.  Oxidative 
stress contributes to reductions in NO bioavailability since NO reacts with reactive oxygen 
species, mainly superoxide (O2-), to destroy NO-producing peroxynitrates4.  In physiological 
settings, endogenous antioxidant systems maintain equilibration between NO and O2-.  In 
hypertension, however, there is an imbalance in this equilibrium which results in increased 
production of O2- and reduced NO bioavailability22.  This imbalance promotes 
vasoconstriction and contributes to local inflammatory responses, leucocyte adhesion, arterial 
remodelling and increased arterial stiffness.  Additional factors which may contribute to 
reduced NO bioavailability include deficiency in L-arginine, the substrate for NO synthase 
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(NOS), increased concentrations of endogenous NO inhibitors, reduced cofactors for eNOS, 
eNOS uncoupling, decreased eNOS expression and altered signal transduction22.  
In the clinical setting, hypertension is associated with increased production of ROS and 
reduced antioxidants.  Ascorbic acid or vitamin C is a ROS scavenger which restores NO 
production and can improve endothelial function in hypertension22.  Ascorbic acid can 
improve vascular responses to acetylcholine in the peripheral and coronary epicardial 
circulations of patients with hypertension4.  This provides further evidence to support the 
contribution of oxidative stress to hypertension-associated endothelial dysfunction and the 
potential benefits of targeting these changes with measures to restore antioxidant balance22.  
Mitochondria are an important source of ROS and mitochondrial oxidative stress is 
implicated in the pathogenesis of hypertension-associated target organ damage.  Dysfunction 
of mitochondrial proteins and interactions between mitochondria and other sources of ROS, 
such as NADPH oxidase, are important contributory factors in the development of 
endothelial dysfunction, cardiac, renal and cerebral end-organ damage associated with 
hypertension39,40. The mitochondria-targeted anti-oxidant MitoQ10 has been shown to protect 
against the development of hypertension, endothelial dysfunction and cardiac hypertrophy in 
young stroke-prone spontaneously hypertensive rats41.  Mitochondria-targeted antioxidants 
may therefore have a role in preventing hypertension-associated target organ changes.  While 
oral antioxidant therapy has not yet been definitely proven to be effective at reducing the risk 
of cardiovascular disease this may reflect the fact that most anti-oxidant approaches to date 
have focused on quenching reactive oxygen species42.  In future, strategies targeted at 
reducing ROS production may be more successful and ongoing research into the protective 
vascular effects of antioxidants should focus on this approach.   
Interactions between NO systems and endogenous vasoconstrictors such as ET-1 and AngII 
may also contribute to the pathogenesis of endothelial dysfunction in hypertension4.  
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Imbalance between NO and ET-1 systems may result in increased ET-1 activity and 
vasoconstriction4,21,43.  AngII also interacts with the NO system to cause NO breakdown via 
AT1 receptors and subsequent activation of NAD(P)H-dependent oxidases that contribute to 
oxidative stress4,44,45. 
3.4 Endothelial Dysfunction and Atherosclerosis 
There is a close association between endothelial dysfunction in hypertension and progression 
of atherosclerosis.  Endothelial dysfunction contributes to platelet aggregation, vascular 
smooth muscle cell proliferation and monocyte adhesion which contribute to progression of 
atherosclerosis and associated plaque rupture and thrombosis4,46-49.  This is a key mechanism 
through which endothelial dysfunction can contribute to increased risk of serious and 
potentially fatal cardiovascular events such as myocardial infarction and stroke.  In patients 
with hypertension, reduced forearm responses to the endothelium-dependent vasodilator, 
acetylcholine, correlate with increased carotid intima-media thickness, a marker of 
atherosclerosis4,50. Furthermore, in a longitudinal study of patients with mild coronary artery 
disease, only those with severe endothelial dysfunction suffered cardiovascular events over 
approximately two years follow-up51.  Similarly, during a follow-up period of approximately 
eight years there was a significant association between coronary endothelial dysfunction and 
risk of cardiovascular events52.  There is also an association between endothelial dysfunction 
as measured by brachial artery flow-mediated dilatation and risk of cardiac events4,53.  
Collectively, these data reinforce the association between hypertension-associated endothelial 
dysfunction and increased risk of cardiovascular events. They support the need to treat both 
the vascular changes associated with hypertension, as well as achieving absolute reductions 
in blood pressure. 
4. Vascular remodelling 
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Vascular remodelling refers to the active process of structural, mechanical and functional 
changes that occur within the vasculature during the initiation and progression  of 
hypertension2,54-56.  The remodelling of small arteries in hypertension is classically associated 
with increased media thickness and may be either eutrophic or hypertrophic depending on 
whether the media cross-sectional area is enlarged (Figure 2).  In eutrophic remodelling, 
which is generally found is essential (primary) hypertension, the media:lumen ratio is 
increased but the media cross-sectional area is not.  Hypertrophic remodelling, which is 
typically found with secondary forms of hypertension such as renovascular hypertension and 
primary aldosteronism, is characterised by an increase in both media:lumen ratio and media 
cross-sectional area54.   
Mechanisms contributing to eutrophic remodelling include expansion of the extracellular 
matrix with collagen deposition and an increased collagen:elastin ratio that results in vascular 
fibrosis and increased arterial stiffening.  Low-grade inflammation also contributes to 
vascular remodelling in hypertension and is characterised by infiltration of inflammatory 
cells, upregulation of inflammatory mediators such as tissue necrosis factor α (TNF-α), 
interleukin (IL)-6, vascular cellular adhesion molecule 1 (VCAM-1), inter-cellular adhesion 
molecule 1 (ICAM-1), nuclear factor (NF)-κB, plasminogen activator inhibitor 1 (PAI-1), 
von Willebrand factor (vWF) and C-reactive protein (CRP)54,56-61.   
5. Oxidative stress 
Oxidative stress contributes to many of the molecular and cellular processes that underpin the 
vascular changes associated with the development of hypertension.  These include pro-
inflammatory responses, oxidative modification of proteins that regulate vascular contraction 
and relaxation, fibrosis and calcification, altered calcium homeostasis and redox-sensitive 
pro-inflammatory and pro-fibrotic transcription factor activation.  Excess production of ROS 
through NADPH oxidase (Nox) and/or reduced antioxidant capacity leads to alteration of 
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vascular function and vascular remodelling62. Oxidative modification of proteins, DNA and 
lipids accumulate in cells and cause impairment of cellular and vascular function with 
activation of molecular mechanisms that result in endothelial and vascular smooth muscle 
cell apoptosis, cell migration and extracellular matrix reorganisation6.  
A state of chronic, low-grade inflammation develops which is regulated by enzyme systems 
that include NADPH oxidases, uncoupled eNOS, xanthine oxidase and the mitochondrial 
respiratory chain62. NADPH oxidases (Nox) are enzymes that produce superoxide by electron 
transfer from NADPH to molecular oxygen and are important sources of ROS and oxidative 
stress in patients with hypertension62.  Nox upregulation is associated with the development 
of endothelial dysfunction and appears particularly important in the pathological vascular 
remodelling observed in hypertension6,63-66.  eNOS normally produces NO via oxidation of L-
arginine to L-citrulline, although under pathophysiological conditions eNOS can transfer 
electrons from NADPH to the oxygen molecule rather than L-arginine, resulting in the 
formation of superoxide instead of NO.  This process is termed eNOS uncoupling62.  
Xanthine oxidase is another potential source of ROS within the vasculature that may 
contribute to oxidative stress associated with hypertension, although its precise role remains 
to be fully understood62.  The mitochondrial electron transport chain can also produce 
superoxide as a by-product of electron transport during oxidative phosphorylation and may 
also therefore contribute to oxidative stress associated with hypertension62.   
The combination of vascular remodelling, inflammation and oxidative stress contribute to the 
progression of atherosclerosis and atherosclerotic cardiovascular disease in patients with 
hypertension, increasing the risk of cerebrovascular disease and ischaemic heart disease.  
6. Arterial Stiffness 
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Hypertension-associated arterial stiffening is contributed to by multiple factors at the 
systemic, vascular, cellular and molecular levels.  These include haemodynamic factors, 
altered vascular contraction and dilatation, ECM remodelling, cytoskeletal organisation, pro-
inflammatory responses and oxidative stress2. There is endothelial cell and vascular smooth 
muscle cell dysregulation, up-regulation of adaptive immune responses, vascular smooth 
muscle cell growth and migration within the media, changes in collagen to elastin ratio within 
the vessel wall and vascular calcification2,6. 
Conduit arteries normally distend to accommodate pressure from the heart during systole and 
facilitate tissue perfusion during diastole.  This physiological feature is predominantly 
determined by the elasticity, distensibility and compliance of the arterial system.  The 
structural changes in the vasculature associated with hypertension result in reduced 
compliance, reduced elasticity and increased arterial stiffness.  This demands greater force 
and pressure to accommodate blood flow and results in further increases in systolic blood 
pressure.  These changes place an increased work load on the myocardium and result in target 
organ damage and left ventricular hypertrophy6.  There is therefore a vicious cycles through 
which hypertension causes increased arterial stiffness which in turn promotes further 
increases in systolic blood pressure and is an independent predictor of future cardiovascular 
events2. Reduced diastolic blood pressure may occur in the context of increased arterial 
stiffness, resulting in widening of the pulse pressure, an important independent predictor of 
future cardiovascular risk6,67.  This may reflect that coronary blood flow occurs 
predominately in diastole and reductions in diastolic blood pressure may therefore reduce 
coronary flow reserve. 
Methods to assess arterial stiffness include measuring pulse wave velocity (PWV), pulse 
wave analysis, augmentation index (AIx), 24-hour ambulatory blood pressure monitoring and 
brachial artery flow-mediated dilatation (FMD)2,68. Increased PWV occurs mainly in the pre-
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hypertensive phase, suggesting that vascular changes may precede the onset of established 
hypertension6. Increased PWV predicts increased risk of cardiovascular morbidity and 
mortality in patients with hypertension, diabetes mellitus and end-stage renal69,66.  PWV may 
therefore be a useful marker to identify patients in the early pre-hypertensive phase and allow 
lifestyle changes to be implemented, alongside blood pressure lowering medication if 
necessary, to prevent worsening high blood pressure and the development of hypertension.   
7. The Extracellular matrix and vascular fibrosis 
The extra-cellular matrix (ECM) is a fundamental component of the connective tissue 
surrounding cells that maintains cellular and vascular integrity, as well as playing a critical 
role in cell signalling and regulation of cell-cell interactions.  Many structural proteins, 
including collagens, elastin, fibronectin and proteoglycans are found within the ECM and the 
relative quantities of collagen and elastin determine a vessel’s biomechanical properties2,70,71.  
There is a dynamic and continuous turnover of these ECM components through tightly 
regulated systems including activation of matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases (TIMPs).  Imbalance in these processes leads to excess 
deposition of proteins, particularly collagen and fibronectin, which contributes to vascular 
fibrosis and stiffening associated with the development of hypertension (Figure 3)2.   
Collagens are the most abundant and stiffest proteins within the ECM and increased collagen 
content, combined with destruction of elastin fibres and a pro-inflammatory 
microenvironment, contributes to ECM remodelling, increased intima-media thickness and 
vascular stiffening in experimental models of hypertension2,71. 
7.1 MMPs and TIMPs 
MMPs are a family of endopeptidases activated by many factors associated with 
hypertension, including pro-inflammatory signalling molecules such as cytokines and 
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interleukins, growth factors, vasoactive agents including Ang II, ET-I and aldosterone, and 
reactive oxygen species (ROS).  The activity of MMPs is regulated at the levels of gene 
transcription, proenzyme activation and activity inhibition2,72. p38MAPK signalling is 
involved in regulating MMP transcription and can enhance or repress MMP expression in a 
cell type-dependent manner.  MMPs are generally activated in the pericellular space by other 
MMPs or serine proteases like plasmin and chymase.  Once activated, they degrade collagen 
and elastin, which results in a modified ECM that is associated with a pro-inflammatory 
microenvironment.  This shifts endothelial and vascular smooth muscle cells to a secretory, 
migratory, proliferative and senescent phenotype that contributes to fibrosis, calcification, 
endothelial dysfunction and increased intima-media thickness, exacerbating vascular 
remodelling and arterial stiffness2. 
Both inhibitory and stimulatory modification of vascular fibrosis by MMPs have been 
observed in hypertension, which most likely reflects activation of different MMP isoforms 
and down-stream signalling pathways2,73.  For example, MMP2 and MMP9 activation by 
TGF-β/SMAD signalling in hypertension is associated with collagen accumulation,  whereas 
MMP8 and MMP13 activation is associated with collagen degradation which may contribute 
to plaque rupture and thrombosis2,74,75.  Furthermore, pro-hypertensive factors such as 
angiotensin II, ET-1 and salt, as well as mechanical shear stresses and physical pressure, 
activate MMP8 and MMP9 and contribute further to hypertension associated vascular fibrosis 
and remodelling.  TIMPs are endogenous inhibitors of MMPs and alterations in the fine 
balance between MMPs and TIMPs in the ECM may contribute to the hypertension-
associated pro-fibrotic phenotype2,73. 
7.2 Transforming Growth Factor-β (TGF-β)/SMAD Signalling 
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Disruption of the transforming growth factor-β (TGF-β) pathway has been associated with 
vascular fibrosis.  There are three isoforms of TGF-β (TGF-β1, -2 and -3), with TGF-β1 
being most commonly associated with ECM remodelling and vascular fibrosis.  TGF-β-1 is 
expressed in endothelial cells, vascular smooth muscle cells, myofibroblasts and adventitial 
macrophages.  Signalling of TGF-β occurs mainly through cytoplasmic proteins which act as 
transcription factors and are known as SMADs.  Vascular TGF-β1 activation and subsequent 
increased SMAD activity increases synthesis of ECM proteins such as fibronectin, collagen 
and plasminogen activator inhibitor-1 (PAI-1)2,76,77.   
TGF-β activation also reduces collagenase production and stimulates TIMP expression, thus 
resulting in excessive accumulation of ECM, in part, due to reduced ECM degradation2,78.  
Additional non-SMAD pathways that contribute to pro-fibrotic signalling via TGF-β include 
ERK, c-JNK, p38 MAPK and PI3K/Akt2,79.  TGF-β1 activation and signalling are increased 
in the aortic wall during the development of hypertension80, whilst angiotensin II81,82, 
mechanical stress77,83, ET-184 and ROS85 all mediate TGF-β activation and contribute to 
vascular fibrosis2.  Furthermore, MMPs, especially MMP2 and MMP9, enhance TGF-β-1 
release, with the result being reduced ECM degradation, further ECM accumulation, vascular 
remodelling and fibrosis2.  
7.3 Plasminogen activator inhibitor-1 
Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of the serine proteases, urokinase-
type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA).  It therefore 
inhibits fibrinolysis, and can regulate fibrin dissolution and inhibit ECM degradation by 
reducing plasmin generation.  In pathophysiological conditions, up regulation of PAI-1 
contributes to ECM protein accumulation and tissue fibrosis by reducing tissue proteolysis 
and collagen degradation2.  PAI-1 activity and expression are up regulated in hypertension 
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and may represent further mechanisms that contribute to the development of a hypertension-
associated, pro-fibrotic phenotype2,86.  
7.4 Galectin-3 
Galectin-3 is an important biomarker of cardiovascular fibrosis expressed on the cell surface 
of cell types including fibroblasts, endothelial cells and inflammatory cells.  It is mainly 
secreted by activated macrophages, whilst other ligands that stimulate galectin-3 secretion 
include collagen, elastin, fibronectin and integrin.  It acts to stimulate cell proliferation, 
adhesion and fibrosis and is important in fibrosis and tissue remodelling2.  In the Prevention 
of Renal and Vascular End-Stage Disease (PREVEND) study, plasma galectin-3 levels 
correlated with cardiovascular risk factors, including hypertension87.  The mechanisms by 
which galectin-3 contributes to ECM remodelling and vascular fibrosis remain unclear but 
JAK, STAT and PKC pathway activation, as well as oxidative stress and inflammation may 
play a role2,88,89.   
7.5 The Renin-Angiotensin-Aldosterone System (RAAS) and Endothelin-1 
The RAAS is critically involved in the functional, structural and mechanical vascular changes 
that occur with the development of hypertension2,6. Ang II, aldosterone and ET-1 activate 
pro-fibrotic pathways and downstream signalling from these agents results in activation of 
redox-sensitive transcription factors, TGF-β-1, MMPs, galectin-3 and MAP kinases that 
contribute to vascular stiffness and fibrosis2,6,90-94. 
7.6 Angiotensin II, Aldosterone and Endothelin-1 
Angiotensin II acts through two receptors – AT1 and AT2, with AT1 activation playing a 
major role in the production of ECM proteins and vascular fibrosis2,95-98.  Whilst the precise 
mechanisms involved in angiotensin II related vascular fibrosis remain to be fully defined, 
increased activity of TGF-β-1, galectin-3, p38 MAPK and MMPs/TIMPs may all contribute.  
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Agents which block angiotensin II activity, such as ACE inhibitors and angiotensin receptor 
antagonists, have been shown to confer vascular protection and improve endothelial function, 
which may be related to increased NO bioavailability6.  Aldosterone is an important mediator 
of vascular remodelling through promotion of vascular hypertrophy, fibrosis, inflammation 
and oxidative stress.  Chronic blockade of mineralocorticoid receptors reduces cardiovascular 
fibrosis in both animal models and clinical trials of hypertension2.   
Endothelin-1 is a potent endogenous vasoconstrictor that is strongly implicated in the 
pathogenesis of hypertension and endothelial dysfunction99-101. As well as evoking 
vasoconstriction, activation of vascular smooth muscle ETAR and ETBR stimulates vascular 
remodelling101,102.  ET-1 has well-established hypertrophic and mitogenic properties and 
stimulates fibroblast-induced collagen synthesis to modulate ECM remodelling.  Treatment 
with an endothelin antagonist normalises expression of the collagen I gene with regression of 
renal vascular fibrosis and improved survival2,103. 
8. Why should we target the vascular system in the treatment of hypertension?  
The association between endothelial dysfunction and hypertension is well established1. The 
endothelium is an important early target of hypertension and endothelial dysfunction is a risk 
marker for future cardiovascular events22.  Targeting the adverse vascular changes associated 
with hypertension should be an additional focus of treatment, in addition to achieving 
absolute reductions in blood pressure (Figure 4)4,22.  This is particularly relevant since 
endothelial dysfunction promotes atherosclerosis and thrombosis, two of the most important 
mechanisms through which hypertension leads to serious cardiovascular sequelae and target 
organ damage4.   
Anti-hypertensive agents with the capacity to reverse endothelial dysfunction as well as 
reducing blood pressure may reverse or prevent the progression of atherosclerosis and 
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thereby reduce the risk of serious complications of hypertension, such as myocardial 
infarction and stroke4. ACE inhibitors, ARBs and calcium channel blockers all have been 
shown to improve endothelial function with associated improvements in markers of oxidative 
stress22.  ACE inhibitors and ARBs reduce the production of ROS, while calcium channel 
blockers have anti-oxidant effects through improvements in the cellular redox and antioxidant 
state (Table 1)4.  β-blockers, despite lowering blood pressure, generally do not improve 
endothelial function.  Nebivolol and perhaps also carvedilol are the exceptions as these β-
blockers may lead to some improvement in endothelial function, since nebivolol has NO 
donor properties and carvedilol may act as a scavenger of oxygen free radicals4,22. 
Anti-hypertensive strategies that improve endothelial function as well as lowering blood 
pressure may be more effective in reducing overall cardiovascular risk than approaches which 
lower blood pressure but have no effect on endothelial function1,24,104.  Indeed, the 
Telmisartan versus Ramipril in renal ENdothelial Dysfunction (TRENDY) study showed that 
both telmisartan and ramipril improved endothelial function in a diabetic population with 
hypertension and early-stage nephropathy105,106.  The Losartan Intervention For Endpoint 
Reduction in Hypertension (LIFE) study, which compared losartan to atenolol-based therapy, 
the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with 
Systolic Hypertension (ACCOMPLISH) trial, which compared ACE inhibitor plus 
amlodipine versus ACE inhibitor plus diuretic, and the Heart Outcomes Protection Evaluation 
(HOPE) study have all shown superior clinical outcomes for treatment strategies which 
include agents that improve endothelial function, such as RAAS blockers and calcium 
channel blockers1,107-110.  The Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial (ALLHAT) trial showed that there were no differences between 
chlorthalidone, amlodipine, or lisinopril in reducing the risk of cardiac death or myocardial 
infarction1,111.  However, ALLHAT included a relatively older population who had almost all 
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been on previous therapy and with an unreported duration of hypertension.  Furthermore, 
blood pressure reductions were greater in the chlorthalidone group, which may account for 
the slightly different picture observed from this study.  It may not be appropriate to generalise 
these findings to younger patients who have a shorter duration of hypertension and less 
vascular disease at baseline1.  
Overall, the evidence would suggest that clinicians should consider the vascular effects of 
anti-hypertensive drugs and non-pharmacological approaches to lowering blood pressure.  
Strategies that improve endothelial function, as well as lowering blood pressure, may achieve 
the best overall improvements in cardiovascular risk for patients.  Furthermore, when 
developing new anti-hypertensive treatments clinicians and scientists should consider 
targeting the adverse vascular changes that contribute to the development  of hypertension, to 
ensure we have drugs that can deliver the absolute best improvements in cardiovascular risk 
for our patients.   
9. Anti-hypertensive drugs and vascular health 
9.1 ACE Inhibitors and angiotensin II receptor blockers  
ACE inhibitors improve endothelial function in animal models and clinical studies of 
hypertension22.  They inhibit bradykinin breakdown and thereby increase plasma 
concentrations of this endothelium-dependent vasodilator4.  This may be one of the 
mechanisms through which ACE inhibitors improve endothelial function in large coronary 
and peripheral arteries4.  
In the spontaneously hypertensive rat (SHR), ACE inhibitors improve endothelium-
dependent responses to acetylcholine112, whilst the ACE inhibitor-diuretic combination 
perindopril-indapamide restores NO production and decreases endothelial contractile 
responses22,113,114.  ACE inhibitors may also have direct protective effects on endothelial 
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function, since in low-renin models of hypertension they have been shown to improve 
endothelial function despite no observed reduction in blood pressure115.   
In clinical studies, ACE inhibitors improve endothelial function in subcutaneous, epicardial, 
brachial and renal circulations, and selectively improve endothelium-dependent vasodilator 
responses to bradykinin4. In patients with essential hypertension, treatment with cizalapril for 
2 years and lisinopril for 3 years improved vascular responses to acetylcholine in the 
subcutaneous microcirculation4,116-118.  Furthermore, within the peripheral circulation, 
perindopril, ramipril, quinapril and the perindopril-indapamide combination improve flow-
mediated dilatation, which most likely relates to increased NO bioavailability and prevention 
of angiotensin-II induced oxidative stress4,35,37,115,119-121. ACE inhibitors may also potentiate 
bradykinin activity, which stimulates release of NO, PGI2 and EDHF from the endothelium22.   
Most studies of ACE inhibitors in hypertension demonstrate greater lowering of central aortic 
than brachial artery BP, suggesting a beneficial effect on arterial compliance69,122.  This may 
in part relate to reduced oxidative stress and increased vasodilatation through inhibition of 
angiotensin II and increased smooth muscle relaxation69,123.  In a randomized, placebo-
controlled crossover study enalapril and perindopril both led to significant improvements in 
peripheral and central BP as well as augmentation index after 4 weeks of treatment.  
Furthermore, there was a greater effect on central than brachial BP, illustrating improvements 
in arterial stiffness69,124.  Acute improvements in arterial stiffness, augmentation index, 
central and brachial BP have been observed 5 hours after administration of ramipril in 
patients with high cardiovascular risk69,123.  In patients with mild essential hypertension both 
enalapril and indapamide reduce brachial BP, mean arterial pressure and pulse pressure, with 
more pronounced effects on central BP and pulse pressure with enalapril compared to 
indapamide.  Enalapril was also associated with improvements in augmentation index, 
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providing further evidence to support the beneficial effects of ACE inhibitors on central BP 
and arterial stiffness69,125.  
ARBs are effective blood pressure lowering agents that may also have beneficial effects on 
endothelial function.  Ang II contributes to endothelial dysfunction through upregulation of 
ET-1, inhibition of NOS via protein Nox4,126,127.  The angiotensin type-1 (AT1) receptor 
antagonist losartan diminishes superoxide production, whilst blockade of AT1 receptors 
allows Ang II to bind to free AT2 receptors and subsequently stimulate AT2-receptor induced 
NO synthesis and release.  This may be one of the mechanisms through which angiotensin II 
receptor blockers can restore NO bioavailability and improve endothelial function4,45,128-130. 
In patients with hypertension, losartan restores vasodilator responses to acetylcholine and 
may also block positive feedback effects of angiotensin II on endothelin synthesis4,131.  
Losartan also has beneficial effects on flow mediated dilatation responses similar to those 
observed with ramipril4,120. Overall, angiotensin II receptor antagonists may have beneficial 
effects on endothelial function in patients with hypertension as a result of increased NO 
release via AT2 receptor stimulation22 and reduced vasoconstrictor responses to ET-14. 
While ACE inhibitors and ARBs have comparable blood pressure-dependent reductions in 
overall cardiovascular risk,  ACE inhibitors also have blood pressure-independent effects in 
reducing the risk of coronary heart disease that have not been observed with ARBs132.  
Furthermore, in patients with type 2 diabetes and overt nephropathy, the ARB olmesartan 
was associated with an increased risk of cardiovascular mortality compared to placebo, 
although there was no difference in risk of major adverse cardiovascular event or all-cause 
mortality133.   It is possible that the bradykinin effects of ACE inhibitors may contribute to 
differential effects of ACE inhibitors and ARBs on coronary artery disease.  Overall, ARBs 
are effective blood pressure lowering agents that reduce cardiovascular risk and should be 
considered in patients intolerant of ACE inhibitors132,134.  
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9.2 Calcium Channel Blockers  
Calcium channel blockers are well-established anti-hypertensive drugs that improve 
endothelial function in both experimental and clinical models of hypertension22,36,115.  This is 
particularly true for the dihydropyridine calcium channel antagonists, such as amlodipine, 
which antagonize the L-type calcium channel and have anti-oxidant effects4,69.  The rate-
limiting calcium channel antagonists such as verapamil and diltiazem may also have 
beneficial effects on endothelial function in patients with essential hypertension, suggesting 
that the benefits of calcium channel antagonists may be a class effect related to NO 
bioavailability4. 
In gluteal resistance arteries from patients with essential hypertension treatment with the 
calcium channel blocker nifedipine for 1 year improved vascular relaxation responses to 
acetylcholine, a finding not observed with atenolol4,135.  Furthermore, within the coronary 
vasculature, nicardipine and diltiazem can reverse endothelial dysfunction in non-stenotic 
segments from patients with hypertension and in stenotic segments from both normotensive 
and hypertensive patients4,136.  Nifedipine exhibits a blood pressure–lowering effect, reduces 
ET-1 induced vasoconstriction and improves endothelium-dependent vasodilation in patients 
with essential hypertension137.  Nifedipine has also been shown to increase coronary vascular 
responses to acetylcholine compared with placebo4.  Amlodipine has been shown to increase 
basal NO release, whilst lacidipine increases vasodilator responses to both acetylcholine and 
bradykinin within the forearm circulation of patients with hypertension4,138.  
Endothelial cells do not express voltage-gated calcium channels and the improvements in 
endothelial function observed with calcium channel blockers are therefore unlikely to be 
calcium-dependent4,139.  Rather, calcium channel blockers  appear to have anti-oxidant effects 
that may protect endothelial cells from oxygen free radicals, thus improving NO 
bioavailability and subsequently improving endothelial function4,140,141. Nifedipine and 
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lacidipine reduce markers of oxidative stress and improve NO bioavailability in patients with 
hypertension and it may be through this mechanism that calcium channel antagonists improve 
vasodilator responses and restore endothelial function in patients with hypertension4,142. 
In patients with end-stage renal disease, nitrendipine significantly reduces brachial and 
central BP, as well as improving PWV and augmentation index, suggesting reduced arterial 
stiffness69,143.  In elderly patients with untreated essential hypertension, both felodipine and 
amlodipine showed a more pronounced effect on central than brachial BP as well as 
improvements in pulse pressure and augmentation index compared to placebo69,124.  This may 
be particularly clinically relevant in the context of elderly patients who are more likely to 
have isolated systolic hypertension with increased pulse pressure and increased arterial 
stiffness.  Hence, dihydropyridine calcium channel blockers may be the most appropriate 
anti-hypertensive drugs in elderly patients.  However, while the dihydropyridine calcium 
channel blockers are associated with improvements in endothelial function, this is to a lesser 
degree than the benefits observed with ACE inhibitors for similar reductions in blood 
pressure.  ACE inhibitors should therefore remain first-line anti-hypertensive drugs used to 
treat younger patients with high blood pressure22.   
9.3 Mineralocorticoid receptor antagonists 
Aldosterone is a mineralocorticoid synthesised by the adrenal cortex and perhaps also in 
blood vessels144,145.  It exerts blood pressure elevating effects through interactions with the 
kidney that influence salt and water balance and may have additional direct effects on blood 
vessels56,145,146. Mineralocorticoid receptor activation may contribute to cardiovascular 
dysfunction, inflammation and fibrosis56.  Spironolactone and eplerenone are 
mineralocorticoid receptor antagonists that are now used frequently as anti-hypertensive 
agents that also improve endothelial function and reduce arterial stiffness.  These benefits are 
at least in part independent of blood pressure reductions, and the additional protective 
 25 
vascular effects of mineralocorticoid receptor antagonists may reflect blockage of 
aldosterone’s pro-inflammatory and pro-fibrotic actions69.   
Spironolactone reduces PWV and augmentation index in patients with essential and resistant 
hypertension147.  Furthermore, aldosterone impairs endothelial function in normal resistance 
vessels, whilst aldosterone can reverse hypertension-related endothelial dysfunction in 
arterioles148.  Similar benefits have been observed with eplerenone which reduces vascular 
stiffness, collagen/elastin ratio, pro-inflammatory mediators and systemic inflammatory 
markers in patients with hypertension. Together, mineralocorticoid receptor blockade reduces 
collagen deposition and vascular stiffness and may also exert additional anti-inflammatory 
benefits beyond absolute reductions in blood pressure52.  Mineralocorticoid receptor 
antagonism may therefore be an effective target to prevent the adverse phenotypical changes 
that occur in the development of hypertension.   
9.4 β-blockers 
There is relatively little evidence to suggest that β-blockers improve endothelial function and 
atenolol may in fact have a negative effect within peripheral subcutaneous and muscle 
microcirculations4. Atenolol treatment for 1 or 3 years did not improve endothelium-
dependent vasodilator responses to acetylcholine or  bradykinin4.  Nebivolol is a selective β1-
blocker which also has vasodilator and NO donor properties, through activation of the L-
Arginine—NO pathways, and may improve endothelial function in patients with 
hypertension through this mechanism4,22,149,150.  
In patients with isolated systolic hypertension both atenolol and nebivolol were associated 
with similar reductions in brachial BP and PWV, whilst pulse pressure was significantly 
lower in the nebivolol group, suggesting nebivolol may have greater beneficial effects on 
arterial stiffness69,151.  Furthermore, in patients with untreated hypertension nebivolol has 
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more pronounced effects on both pulse pressure and augmentation index69,152.  Nebivolol was 
also compared with metoprolol in a randomized, double-blind study involving 80 patients and 
whilst similar effects were seen in terms of brachial BP, mean arterial pressure, augmentation 
index and PWV, nebivolol was associated with significantly greater improvements in central 
aortic BP, pulse pressure and LV septal wall thickness.  Furthermore, the changes in septal 
wall thickness correlated with reductions in central aortic blood pressure and pulse pressure, 
suggesting these changes related to improvements in blood pressure rather than a direct 
cardio-protective effect.  Overall, the potential beneficial vascular effects of nebivolol appear 
most likely related to enhanced release of endothelium-derived NO with associated 
improvements in endothelial function and reduced arterial stiffness69,153.   
Carvedilol is another selective β1-blocker that also has α1-adrenoceptor antagonistic 
properties as well as strong anti-oxidant effects and as such may improve endothelial function 
through this mechanism4.  As a general class of drugs however, β-blockers are less effective 
in improving endothelial function than RAAS blockers and calcium channel blockers4. 
9.5 SPRINT Trial 
Recent data from the SPRINT trial have suggested that aggressive lowering of blood 
pressure, to less than 120 mmHg systolic, may be effective at reducing the risk of major 
cardiovascular events and death in selected patients with hypertension5.  The intensive 
treatment group in the SPRINT trial was characterised by patients who received a number of 
anti-hypertensive agents, including RAAS blockers and calcium channel blockers.  The 
reductions in cardiovascular risk observed in the intensive treatment group in SPRINT may 
therefore be explained, at least in part, by the combined protective vascular effects of these 
drugs, as well as the observed reductions in blood pressure.   
10. Other strategies to improve vascular health in hypertension 
 27 
Lifestyle modifications including dietary improvements, reduced salt consumption, exercise, 
weight loss and smoking cessation all reduce cardiovascular risk and should be strongly 
encouraged in all patients154,155. Maintaining normal body weight, restricting salt intake, 
limiting alcohol consumption to ≤ 3 units/day for men and ≤ 2 units/day for women, engaging 
in regular physical exercise, consuming at least 5 portions of fruit and vegetables and 
reducing dietary intake of total and saturated fat are important lifestyle modifications 
suggested by major hypertension guidelines.  Lifestyle advice should be reinforced at regular 
intervals as this approach can prevent age-associated increases in blood pressure and may 
avoid progression to anti-hypertensive drug therapy in patients with borderline high blood 
and complement blood pressure lowering effects of anti-hypertensive drugs in treated 
patients154.  
10.1 Diet 
The British Hypertension Society and American Heart Association make specific 
recommendations for dietary interventions that can lower blood pressure 3,156,157 and likely 
improve vascular health. In patients with normal blood pressure or prehypertension, dietary 
changes can reduce blood pressure and thereby reduce the risk of hypertensive complications.  
When applied at a population level, this results in significant public health benefits. A 3 
mmHg reduction in BP is associated with 8% reduction in stroke mortality and 5% reduction 
in mortality from ischaemic heart disease157,158.  In treated hypertensive patients, dietary 
changes, particularly reduced salt intake, can lower BP and lead to a reduced number of 
medications required to achieve BP control157.  
10.2 Salt Intake 
Dietary salt intake is associated with increased blood pressure157 and reduced salt intake is an 
essential lifestyle measure in treating high blood pressure.  Reducing dietary salt intake can 
 28 
reduce systolic blood pressure by as much as 5 mmHg in patients with hypertension157,159.  
Clinical studies have shown that reduced salt consumption can also prevent hypertension, as 
well as lowering BP and facilitating better BP control in patients treated for 
hypertension157,160-164.  These improvements may be related to improved endothelial  function 
since the hypertensive effect of salt loading appears linked to oxidative stress and reduced 
NO bioavailability, which can be exacerbated by NO inhibition1,165-167.  In patients with mild 
hypertension those with lower self-reported daily sodium intake had significantly higher 
brachial artery flow-mediated dilatation, suggesting improved endothelial function in patients 
with lower sodium intake1,168.   
Guidelines recommend a sodium intake of < 100 mmol/day157,169,170, which is felt to be 
realistic and achievable given currently available food supplies.  However, approaches to 
lower salt intake and achieve associated improvements in vascular function and blood 
pressure should be focussed at a population level.   More than 75% of salt consumed comes 
from processed foods and food manufacturers and restaurants should aim to progressively 
lower the salt content of the food by 50%157,169,171,172.  
10.3 Fruit, Vegetables and Fish 
Increased intake of fruit, vegetables and fish is a key lifestyle factor that can reduce blood 
pressure in patients with hypertension.  This is best-evidenced from the DASH (Dietary 
Approaches to Stop Hypertension) trial where increased fruit, vegetable and fish 
consumption, combined with reductions in saturated fat and dairy products, significantly 
reduced blood pressure amongst patients with hypertension who were not previously taking 
medication156,173.  Similarly, the Lyon Diet Heart Study found that specific dietary advice to 
increase fruit, vegetable, fish and α–linolenic acid consumption after myocardial infarction 
was strongly associated with reduced cardiovascular mortality.  This led the study to be 
stopped after only 12 months due to a clear benefit which persisted after 5 years156,174,175.   
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Furthermore, in a study of fruit and vegetable intake in patients with hypertension conducted 
over 12-weeks, each additional portion of fruit and vegetable consumed per day was 
associated with an approximately 6% improvement in endothelium-dependent forearm blood 
flow responses, measured using venous occlusion plethysmography156.  This may be related 
to high polyphenol content in fruit and vegetables which can increase NO 
bioavailability1,156,176,177.  There was also a trend towards reduced systolic blood pressure 
with increasing fruit and vegetable consumption, although the study was not powered to 
detect differences in this endpoint.  Importantly, there was no improvement in forearm 
vascular responses to the endothelium-independent vasodilator sodium nitroprusside, which 
suggests that the beneficial effects of fruit and vegetable intake are related to protective 
effects on the endothelium156.  The data from this study are in contrast to forearm 
plethysmography studies that assessed the effect of ascorbic acid on forearm vascular 
responses and suggest that a balanced, pragmatic approach that considers whole food and 
dietary patterns may be the best means of improving the overall vascular phenotype of 
patients with hypertension156,178-180.  Increased fruit and vegetable consumption may also 
make patients more likely to adopt other favourable dietary modifications, such as reduced 
salt and fat consumption.   
Overall relatively small and achievable increases in fruit and vegetable intake are associated 
with improvements in a vascular measure of clinical prognostic value.  When extrapolated to 
a population-level these data suggest that clinically relevant reductions in blood pressure can 
be achieved through simple dietary interventions.  Furthermore, while endorsing the “5-a-
day” public health message for increased fruit and vegetable consumption, it also suggests 
that smaller increases in fruit and vegetable intake still have prognostic benefits.  This is an 
important public health message that must be clearly conveyed to the public: small increases 
in fruit and vegetable intake are beneficial, since some individuals may perceive a target of 5-
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a-day unattainable156.  Increased consumption of fruit, vegetable and fish improves 
endothelial function and reduces blood pressure and should therefore be strongly encouraged 
to all in society, including patients with hypertension or borderline high blood pressure and 
the wider community, as part of public health campaigns3,154,156.  
10.4 Weight Loss 
Weight loss reduces blood pressure and even modest reductions can prevent hypertension by 
approximately 20% in individuals who are pre-hypertensive and overweight157,160.  
Furthermore, approximately 5 kg weight loss, which should be achievable for most 
individuals, can reduce systolic blood pressure by over 4 mmHg.  When applied to a 
population, relatively small individual changes could therefore translate into significantly 
reduced cardiovascular morbidity and mortality157,181.  Overall, evidence strongly supports 
weight reduction in the prevention and treatment of high blood pressure and maintenance of a 
BMI <25 kg/m2 appears the most effective target157.  It is important to ensure that any 
reductions in weight are sustained to maintain cardiovascular benefits157. 
10.5 Alcohol Consumption 
Alcohol intake and blood pressure are positively associated, particularly at greater than two 
units of alcohol per day, independent of potential confounders such as age, obesity and salt 
intake157,182,183.  Furthermore, there is a dose-dependent relationship between percentage 
reduction in alcohol intake and reduced blood pressure157,183.  Light alcohol consumption may 
confer some protection against ischaemic heart disease and alcohol consumption should 
therefore be limited to ≤ 3 units per day for men and ≤ 2 units per day for women, whilst 
patients with hypertension who drink excessively should be strongly encouraged to reduce 
their alcohol intake3,154.   
10.6 Exercise 
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Regular exercise can reduce blood pressure and patients should be encouraged to exercise for 
at least 30 minutes on most days of the week and at least 3 days of the week3,154.  Regular 
exercise protects against the development of arterial stiffness and endothelial dysfunction that 
occur with advancing age184 and it is likely that exercise has similar beneficial vascular 
effects in patients with hypertension.  Aerobic exercise reduces oxidative stress and 
inflammation and restores NO bioavailability184.  Interestingly, whilst aerobic exercise 
reduces arterial stiffness, resistance training alone may in fact increase arterial stiffness and 
resistance training should therefore be combined with aerobic training to ensure 
cardiovascular benefits are maintained184.  The vascular benefits of exercise may be most 
marked with high intensity training, since moderate physical activity improves endothelial 
function but had no effect on arterial stiffness after 12 weeks185.  Future research should aim 
to determine the dose-response effect of physical activity and improvements in vascular 
function.  In animal studies, increased physical activity reduces carotid artery stiffness and 
reverses makers of oxidative stress, collagen types I and III, and the pro-fibrotic cytokine 
TGF-β1184,186.  Overall, this suggests that aerobic exercise may reverse arterial stiffening by 
normalizing key structural factors and markers of oxidative stress within the vasculature184. 
In clinical studies, aerobic exercise improves brachial artery flow-mediated dilatation in older 
males and females with low oestrogen but not women treated with oestrogen 
supplementation184,187,188.  This suggests that oestrogen may be permissively involved in the 
beneficial effects of aerobic exercise on endothelial function in women184.  Aerobic exercise 
also improves forearm vascular responses to acetylcholine in older men when assessed using 
venous occlusion plethysmography184,189 and the observed differences can be abolished by 
inhibition of eNOS, suggesting that the benefits of aerobic exercise are at least in part 
mediated by increased NO bioavailability184,190. 
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Aerobic exercise suppresses oxidative stress within the vasculature through inhibition of pro-
oxidant pathways and stimulation of antioxidant mechanisms184.  In old previously sedentary 
mice, a 3-month programme of voluntary wheel running reduced aortic nitrotyrosine and 
NADPH oxidase expression184,191.  In clinical studies, aerobic exercise restores SOD 
expression and activity in sedentary older men to levels seen in younger men184,192. Reduced 
vascular inflammation may be another mechanism through which aerobic exercise improves 
vascular structural and function184.  In mouse models, 10-14 weeks of voluntary running is 
associated with reduced expression of NF-κB and pro-inflammatory cytokines184,193.  Vitamin 
C infusion improves flow-mediated dilatation in older sedentary men and oestrogen-deficient 
women, reinforcing the concept that reduced oxidative stress is a key mechanism through 
which aerobic exercise can reduce vascular inflammation and improve endothelial 
function184,187,190,194.  Aerobic exercise may also protect the vasculature from adverse effects 
of other cardiovascular risk factors such as elevated LDL cholesterol and impaired glycaemic 
control184,195,196.  This potential benefit of aerobic exercise also appears to be mediated by 
reduced oxidative stress and improved NO bioavailability184,197. 
10.7 Smoking cessation 
Smoking is one of the most important preventable risk factors for the development of 
atherosclerosis and potentially devastating cardiovascular sequelae such as myocardial 
infarction and stroke198,199.  Smoking causes 6 million deaths per year and accounts for 10% 
of all cases of cardiovascular disease199,200.  It contributes to the initiation and acceleration of 
vascular injury and atherosclerotic cardiovascular disease through endothelial dysfunction, 
oxidative stress, reduced NO bioavailability, vascular inflammation, increased arterial 
stiffness and a shift towards a pro-thrombotic state198,199.  Smoking reduces brachial artery 
FMD in a dose-dependent manner, as a result of reduced NO bioavailability within the 
vasculature199,201.  
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Cigarette smoke contains oxidants and free radicals that contribute to a pro-oxidative 
environment through lipid oxidation and oxidative modification of biomolecules199,202.  This 
shift towards a pro-oxidative state is characterised by activation of NADPH oxidases which 
increase ROS generation and leads to reduced NO bioavailability199.  The pro-oxidative 
environment also contributes to local and systemic immune system activation and 
inflammation199.  Smokers have increased concentrations of neutrophils, lymphocytes and 
monocytes, as well as pro-inflammatory factors TNF-α, IL-1β, and CRP199,203-207.  Increased 
local inflammation is illustrated by increased expression of IL-6, Il-8 and VCAM-1199,208.  
Inflammation and oxidation contribute to activation of macrophages, endothelial cells and 
platelets, with subsequent endothelial cell damage, dysfunction and premature cell death199.  
Smoking also increases vascular smooth muscle cell proliferation and migration through 
activation of the platelet-derived growth factor-protein kinase C signalling cascade and 
alterations in the extracellular matrix and tissue remodelling through increased expression of 
matrix metalloproteinases (MMP-1/8/9)199,209-211.  Overall, smoking contributes to endothelial 
damage and dysfunction, with a shift towards a pro-oxidative and pro-inflammatory state that 
accelerates atherogenesis and increases the risk of atherosclerotic cardiovascular events199.   
The effects of smoking on blood pressure are less well defined.  Whilst smoking causes acute 
increases in blood pressure and is associated with malignant hypertension, any chronic 
independent effects of smoking on blood pressure appear small212,213.  A number of studies 
have found that smokers generally have BP levels equivalent to or lower than non-
smokers212,214,215.  However, these studies are generally based upon isolated clinic blood 
pressures and therefore are unlikely to reflect blood pressure trends occur over the course of a 
day.  This is particularly relevant in smokers who may be exposed to a number of periods of 
acute blood pressure rises over the course of a day, around the times when they are smoking.  
Indeed, in a study of 24-hour ambulatory BP monitoring smokers maintained higher average 
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daytime systolic blood pressures than non-smokers, despite similar clinic blood 
pressures212,216.  Given the recent emphasis on 24-hour ambulatory monitoring to diagnose 
and monitor high blood pressure, this investigation should perhaps be considered more 
readily in smokers and not be inappropriately reassured by isolated clinic blood pressure 
measurements212.  The acute rises in blood pressure to which smokers are exposed to are 
likely to be harmful and all smokers should be encouraged to stop3,154.  Furthermore, it is well 
established that smoking exerts toxic effects on the endothelium which, combined with the 
adverse vascular effects of high blood pressure, leads smoking and hypertension to have 
synergistic deleterious effects on vascular function and overall cardiovascular risk212. 
Smoking cessation is therefore one of the most important lifestyle changes that patients with 
high blood pressure can make to reduce their overall cardiovascular risk3,154,198. 
11. Conclusions 
Hypertension is characterised by a phenotype of vascular changes that include endothelial 
dysfunction, increased vasoconstriction, vascular remodelling, inflammation, fibrosis and 
increased arterial stiffness.  These factors work in synergy with high blood pressure to 
increase cardiovascular risk through further increases in blood pressure and progression of 
atherosclerosis. Hypertension is an increasing public health burden with many patients having 
sub-optimal blood pressure control, putting them at increased risk of hypertension-associated 
target organ damage and cardiovascular disease. With the many antihypertensive drugs 
available (69 approved by the FDA)201 optimal treatment remains a challenge. This may be 
due, in part, to the fact that many of these drugs do not specifically target the vascular system 
to ameliorate vascular damage associated with hypertension.  However, some of the effective 
antihypertensive drugs currently used do promote vascular health, such as ACEIs, ARBs, 
calcium channel blockers and mineralocorticoid receptor blockers. Some newer 
cardiovascular drugs, such as agonists of the AT2R, vasopeptidase inhibitors, dual acting 
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ARB-neprilysin inhibitors, and ET-1 receptor blockers, may have potent blood pressure-
lowering actions as well as positively influencing vascular function. The key outstanding 
study is one which compares standard guideline based therapy to endothelial function 
directed therapy, in order to determine the overall clinical efficacy of an endothelial targeted 
approach.  Lifestyle factors can also contribute to the vascular changes associated with high 
blood pressure and patients should therefore be encouraged to reduce dietary salt intake, 
maintain a healthy body weight, engage in regular aerobic exercise, consume fish, fruit and 
vegetables, moderate their alcohol consumption and not smoke.  Pharmaceutical development 
should focus on collaboration to develop new blood pressuring lowering treatments that 
better target the vascular changes associated with hypertension. Advancing knowledge in the 
understanding of vascular mechanisms that cause high blood pressure will facilitate efficient 
drug discovery to reduce the enormous clinical and economic burden of hypertension. 
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Table 1 
 
Anti-hypertensive drugs and beneficial vascular effects 
 
Drug class Example drugs Possible beneficial vascular effects 
ACE inhibitors 
Lisinopril 
Perindopril 
Enalapril 
Ramipril 
↑ NO bioavailability,  
↓ Production of reactive oxygen species  
Vasodilation, anti-inflammatory 
Angiotensin-II receptor 
blockers 
Losartan 
Valsartan 
Candesartan 
↑ NO bioavailability 
↓ Production of reactive oxygen species  
Vasodilation, anti-inflammatory 
Calcium channel 
blockers 
Amlodipine 
Lercanidipine 
Nifedipine 
Improved cellular redox state 
Mineralocorticoid 
receptor antagonists 
Spironolactone 
Eplerenone 
↓ Pro-inflammatory/pro-fibrotic changes 
β-blockers 
Nebivolol 
Carvedilol 
↑ NO bioavailability 
Reactive oxygen species scavenger 
ACE, angiotensin converting enzyme; NO, nitric oxide. 
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Figure legends 
Figure 1 
Factors contributing to vascular changes associated with hypertension.  Activation of pro-
inflammatory, pro-fibrotic, redox-sensitive and growth/apoptotic pathways lead to structural, 
functional and mechanical changes with arterial remodelling, vascular calcification and 
endothelial dysfunction. RAAS, renin angiotensin aldosterone system; Ang II, angiotensin II, 
ET-1, endothelin-1; NO, nitric oxide. 
 
 
Figure 2 
Schematic demonstrating changes that occur during vascular remodelling associated with 
hypertension. Vascular remodelling is associated with an increase in media-to-lumen ratio  
(M:L) and variable changes in cross sectional area (CSA). 
 
Figure 3 
Extracellular matrix remodelling in hypertension.  Angiotensin II, aldosterone, ET-1 and 
other hypertensive factors promote ECM remodelling through activation of transforming 
growth factor-β (TGF-β), mitogen-activated protein kinase (MAPK) and SMAD pathways 
and reactive oxygen species (ROS).  This leads to matrix metalloproteinase (MMP) and 
connective tissue growth factor (CTGF) activation and upregulation of galectin-3.  Collagen, 
fibronectin and proteoglycan deposition is increased, which leads to fibrosis and increased 
arterial stiffness.  Adapted from Harvey, et al. 2016. 
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Figure 4 
Therapeutic approaches to promote vascular health and improve vascular function in 
hypertension. Antihypertensive drugs and lifestyle modifications can repair and ameliorate 
vascular damage. These vascular actions together with blood pressure-lowering effects 
reduce cardiovascular risk and complications of hypertension. 
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